Pneumocystis pneumonia associated with infliximab in Japan.
Harigai
Masayoshi
M
Koike
Ryuji
R
Miyasaka
Nobuyuki
N
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016022:Case-Control Studies; D006801:Humans; D000069285:Infliximab; D007564:Japan; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D016016:Proportional Hazards Models; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab